Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 78

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 78

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 79

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 79

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 80

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 80

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 81

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 81

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 82

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 82

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 83

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 28, 2020

Pembrolizumab

Approved submission · SUPPL 83

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 23, 2020

Sildenafil citrate

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 23, 2020

Acyclovir

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 21, 2020

hydrochlorothiazide

Approved submission · SUPPL 26

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 14, 2020

hydrochlorothiazide

Approved submission · SUPPL 16

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 13, 2020

hydrochlorothiazide

Approved submission · SUPPL 4

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 10, 2020

Oxaliplatin

Approved submission · SUPPL 12

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 7, 2020

Glimepiride

Approved submission · SUPPL 14

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 7, 2020

Acyclovir

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 6, 2020

Omeprazole

Approved submission · SUPPL 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 6, 2020

Omeprazole

Approved submission · SUPPL 4

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 6, 2020

Omeprazole

Approved submission · SUPPL 7

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionApril 6, 2020

Oxaliplatin

Approved submission · SUPPL 16

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →